The present therapy intends to be an homogeneous treatment for AML patients based on a
pretreatment with hydroxiurea plus an induction therapy with the standard arm with
Daunorubicine as according to EORTC-GIMEMA AML10 study.
The post-remissional treatment is based on transplant with HLA compatible donor is foreseen
for all patients and autologous transplant for those without HLA compatible donor available.